XCURHealthcare · Biotechnology

XCUR Stock Forecast: Exicure, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026

$1.37

−2.14% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 14 Sept 2026 — in the lower half.

Market cap

$9.0M

Ticker Nerd rank

45 / 100

Median analyst target

—

Analysts covering

Revenue$0.0

Operating income−$1.1M

Net income−$1.1M

Free cash flow−$887K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+9.6%

YTD

−74.7%

−64.6%

From 52W high

−81.2%

From 52W low

+19.1%

$1.15

$7.29

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

XCUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Exicure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026

45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Issuance

Growth

Volatility

Value

Quality

Revisions

Momentum

Size (93): Smaller than most of the companies we track.

Momentum (12): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XCUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XCUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Recent analyst actionsNewest first

Of the 10 most recent actions, 2 moved their price target up and 3 moved it down.

Date	Firm	Action	Rating	Target
16 Aug 2022	Chardan Capital	Maintains	Neutral	$0.25 → $2.00
13 Dec 2021	Chardan Capital	Downgrade	Neutral	$2.25 → $0.40
23 Nov 2021	Chardan Capital	Maintains	Buy	$7.00 → $2.25
17 May 2021	HC Wainwright & Co.	Maintains	Buy	$8.00 → $6.00
18 Dec 2020	BMO Capital	Initiates	Outperform	—
17 Sept 2020	Chardan Capital	Maintains	Buy	$5.00 → $7.00
20 Nov 2019	Guggenheim	Initiates	Buy	—
6 Nov 2019	H.C. Wainwright	Initiates	Buy	—
26 Mar 2019	Chardan Capital	Initiates	Buy	—
11 July 2018	Ladenburg Thalmann	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XCUR appears on the weeks it earns a place.

Performance

XCUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Exicure, Inc. returned −64.6% against +17.0% for the S&P 500, dividends included.

XCUR vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XCUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Exicure, Inc. (XCUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.2×
Price / sales: —
Price / book: 4.2×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −168.4%
Return on assets: −30.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Exicure, Inc. (XCUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Exicure, Inc. has a market value of $9.0M and an enterprise value of $7.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.3M.
Free cash flow in the twelve months to 30 June 2026: −$6.4M.
Shares outstanding: 6.4M.
Trailing P/E: 0.2×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Exicure, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

XCUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
XCURExicure, Inc.	$9.0M	45
SKYESkye Bioscience, Inc.	$8.8M	36
ALZNAlzamend Neuro, Inc.	$8.4M	33
CNSPCNS Pharmaceuticals, Inc.	$8.3M	22
IMNNImunon, Inc.	$8.2M	23
ENSCEnsysce Biosciences, Inc.	$9.4M	37
SNTISenti Biosciences Holdings, Inc.	$9.4M	54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Exicure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XCUR news & analysis

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewsWire · 3 Aug 2026neutral

Exicure, Inc. announced it expects to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.

Why it matters — XCUR watchers would note the company is meeting a contractual milestone obligation by issuing equity rather than paying cash, which affects its share count.

FAQ

Frequently asked questions about XCUR stock

Is XCUR stock a buy right now?

Of the 1 analysts covering Exicure, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exicure, Inc. 45 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XCUR?

As at 14 Sept 2026, Exicure, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the XCUR stock forecast for 2030?

No analyst covering Exicure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XCUR are extrapolating price history, which says nothing about the business.

How has XCUR stock performed over the past year?

Exicure, Inc. returned -64.6% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exicure, Inc. do?

Exicure Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapies and related drug candidates.

What is the latest news on XCUR?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance". Exicure, Inc. announced it expects to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.

Company

About Exicure, Inc.

Exicure Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapies and related drug candidates. The company uses its proprietary spherical nucleic acid platform to design treatments aimed at validated biological targets, with current work spanning immuno-oncology, inflammatory diseases, genetic disorders, neurological disorders, and hair loss. Exicure’s research and development activities center on advancing RNA-targeted medicines and other therapeutic programs that address conditions with limited treatment options. The company operates as a specialized drug development business within the biotechnology sector, combining in-house discovery capabilities with a platform-based approach to therapeutic design. Exicure Inc. plays a niche role in the market as a developer of next-generation genetic medicine technologies and targeted therapeutics.

CEO Mr. Jungsoo Kim · 2 employees · United States · https://www.exicuretx.com